• Grazoprevir Hydrate: From Protease Biology to Translation

  2026-10-05

  A source-grounded perspective on Grazoprevir hydrate and MK-5172 hydrate, connecting NS3/4A protease biology with genotype-aware validation, resistance research, and translational strategy.

• DRB: Research Context, Mechanisms, and Limits

  2026-10-05

  DRB is a research compound used to study transcriptional elongation and cyclin-dependent kinase activity. This overview compares supplier-reported biochemical and cellular findings with peer-reviewed evidence on YTHDF1-driven stem-cell fate transitions, emphasizing mechanistic boundaries, evidence strength, and the absence of direct evidence connecting DRB to that transdifferentiation model.

• Parthenolide, ROS, and Lymphoid Cancer Apoptosis

  2026-10-04

  Jorge and colleagues used a resazurin-based cell viability assay alongside flow cytometry and gene-expression analysis to examine parthenolide responses across seven lymphoid malignancy cell lines. The study links reduced metabolic activity with apoptosis, oxidative stress, glutathione loss, and mitochondrial membrane-potential disruption, while showing that response mechanisms vary by cell line.

• AO/PI Staining Solution for Mechanistic Cell Counting

  2026-10-03

  AO/PI Staining Solution provides a membrane-integrity view of cell populations that can strengthen interpretation of diabetic nephropathy research. This article connects fluorescent live/dead measurements with the phillygenin study while clarifying what the assay can—and cannot—prove about inflammation and apoptosis.

• β-Pseudouridine: Designing Causal RNA Assays

  2026-10-02

  β-Pseudouridine is a C-glycoside isomer of uridine with important effects on RNA structure and translational fidelity. This article develops a causal assay framework for distinguishing nucleoside chemistry from RNA platform effects, using recent self-amplifying influenza vaccine findings as a practical case study.

• SARS-CoV-2 Release Factors Revealed by RNAi

  2026-10-01

  Kerr et al. used an arrayed, druggable-genome RNA interference screen with two-timepoint viral RNA measurements to identify host factors acting across the SARS-CoV-2 replication and reinfection cycle. The study gives particular weight to Rab11a-linked vesicular transport and shows that pharmacological CDK9 inhibition can block viral release, while also clarifying the limitations of translating host-factor screens into antiviral strategies.

• 2,2,2-Trichloroethanol in Protein Workflows

  2026-10-01

  Use 2,2,2-Trichloroethanol as a flexible protein analysis reagent for rapid in-gel visualization, assay development, and molecular biology research. This guide connects practical electrophoresis optimization with the orthogonal imaging strategy reported for assessing dopaminergic neuron maturation in a Parkinson’s disease model.

• Fluorescein TSA Fluorescence System Kit Guide

  2026-09-30

  The Fluorescein TSA Fluorescence System Kit provides a spatially precise strategy for detecting scarce targets in fixed retinal and vascular samples. This guide connects tyramide chemistry with the blood–retinal barrier findings of a mechanistic diabetic retinopathy study and explains how to design, control, and interpret amplified fluorescence assays.

• X-Gal: Reliable β-Galactosidase Workflows

  2026-09-30

  A scenario-based guide to selecting, preparing, and interpreting X-Gal in blue-white colony screening and β-galactosidase activity assays. It explains how SKU A2539 supports reproducible molecular cloning while clarifying the limits of using a chromogenic reporter as a proxy for cell viability or cytotoxicity.

• Bromodomain Inhibitor (+)-JQ1: Mechanism & Uses

  2026-09-29

  Bromodomain Inhibitor, (+)-JQ1 is a selective BET bromodomain inhibitor used to study BRD4, BRDT, transcriptional control, apoptosis, inflammation, and spermatogenesis. Its strongest use is as a mechanistic research probe, not as a validated clinical treatment.

• Cannabidiol in Orofacial Inflammatory Pain

  2026-09-29

  A 2026 Brain Research Bulletin study shows that cannabidiol can reduce both inflammatory orofacial nociception and pain-associated affective and cognitive deficits in mice. Its main contribution is a compartment-specific mechanism linking peripheral CB2 activity, central CB1 signaling, endocannabinoid changes, and serotonin dynamics in the central amygdala.

• Novobiocin: Mechanism, Evidence, and Protocols

  2026-09-28

  Novobiocin is an aminocoumarin antibiotic that inhibits bacterial DNA gyrase subunit B and modulates Hsp90. Evidence also supports its evaluation as an antiparasitic agent and antiviral compound, but antiviral findings remain in vitro and should not be treated as clinical efficacy.

• GS967: Cardiac Late Sodium Current Inhibitor

  2026-09-28

  GS967 is a potent cardiac late sodium current inhibitor used to study pathological sodium influx, cellular calcium loading, and cardiac electrophysiology. Product information reports activity in ventricular myocytes and isolated hearts, while aging-mouse research supports late sodium current as a mechanism linking delayed repolarization with impaired relaxation.

• FLT3–TAZ Signaling Drives Drug Resistance in BP-CML

  2026-09-27

  Shin et al. identify FLT3 expression as a marker of poor prognosis and a driver of BCR::ABL1 tyrosine kinase inhibitor resistance in blast phase chronic myeloid leukemia (BP-CML). Their findings connect FLT3 to a JAK–STAT3–TAZ–TEAD–CD36 signaling axis and suggest that targeting FLT3 signaling, or using ponatinib, may help overcome resistance in experimental models.

• Quizartinib (AC220): FLT3 Assay Workflows

  2026-09-26

  Build a practical FLT3 inhibition workflow with Quizartinib (AC220), from rapid target-engagement checks to longer-term AML cell-response measurements. The article also explains how to use this selective research tool to investigate FLT3-associated resistance in other models without overstating what the evidence shows.

8048 records 1/537 page Next 12345 下5页 Last page